Phase IV, multicenter study to evaluate the correlation of the overall objective response according to RECIST criteria v1.1. assessed by conventional imaging techniques, the morphologic response by CT and pathologic response after the resectability of liver metastases secondary to colorectal cancer treated with bevacizumab in combination with XELOX.

Trial Profile

Phase IV, multicenter study to evaluate the correlation of the overall objective response according to RECIST criteria v1.1. assessed by conventional imaging techniques, the morphologic response by CT and pathologic response after the resectability of liver metastases secondary to colorectal cancer treated with bevacizumab in combination with XELOX.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 May 2012

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Acronyms AVAMET
  • Most Recent Events

    • 23 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top